Ligand Pharmaceuticals (LGND) Competitors $184.49 +1.33 (+0.73%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$184.44 -0.06 (-0.03%) As of 10/8/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock LGND vs. ADMA, ANIP, NBIX, EXEL, IONS, EXAS, BMRN, MDGL, RGEN, and HALOShould you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include ADMA Biologics (ADMA), ANI Pharmaceuticals (ANIP), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Ionis Pharmaceuticals (IONS), Exact Sciences (EXAS), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "medical" sector. Ligand Pharmaceuticals vs. Its Competitors ADMA Biologics ANI Pharmaceuticals Neurocrine Biosciences Exelixis Ionis Pharmaceuticals Exact Sciences BioMarin Pharmaceutical Madrigal Pharmaceuticals Repligen Halozyme Therapeutics ADMA Biologics (NASDAQ:ADMA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability. Which has preferable valuation & earnings, ADMA or LGND? ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M8.18$197.67M$0.8617.00Ligand Pharmaceuticals$187.58M19.27-$4.03M-$4.00-46.12 Which has more risk and volatility, ADMA or LGND? ADMA Biologics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Is ADMA or LGND more profitable? ADMA Biologics has a net margin of 44.06% compared to Ligand Pharmaceuticals' net margin of -40.44%. ADMA Biologics' return on equity of 41.01% beat Ligand Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics44.06% 41.01% 28.47% Ligand Pharmaceuticals -40.44%-9.21%-8.09% Do analysts recommend ADMA or LGND? ADMA Biologics currently has a consensus target price of $27.67, indicating a potential upside of 89.24%. Ligand Pharmaceuticals has a consensus target price of $176.50, indicating a potential downside of 4.33%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities research analysts plainly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Ligand Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media favor ADMA or LGND? In the previous week, Ligand Pharmaceuticals had 1 more articles in the media than ADMA Biologics. MarketBeat recorded 4 mentions for Ligand Pharmaceuticals and 3 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.84 beat Ligand Pharmaceuticals' score of 0.48 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in ADMA or LGND? 75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 3.5% of ADMA Biologics shares are held by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryADMA Biologics beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LGND vs. The Competition Export to ExcelMetricLigand PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.59B$3.35B$6.10B$10.55BDividend YieldN/A2.28%5.69%4.75%P/E Ratio-46.1221.5785.4727.60Price / Sales19.27427.64582.22224.03Price / Cash113.9947.1237.9261.55Price / Book4.2010.1413.136.76Net Income-$4.03M-$52.31M$3.30B$275.88M7 Day Performance2.43%5.14%4.29%2.81%1 Month Performance11.54%14.68%9.45%9.24%1 Year Performance78.70%30.98%86.64%35.42% Ligand Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LGNDLigand Pharmaceuticals3.8776 of 5 stars$184.49+0.7%$176.50-4.3%+79.2%$3.59B$187.58M-46.1280Analyst ForecastADMAADMA Biologics3.6893 of 5 stars$14.73+1.3%$27.67+87.9%-29.4%$3.51B$426.45M17.12530Analyst ForecastANIPANI Pharmaceuticals3.6285 of 5 stars$90.83+1.9%$97.29+7.1%+61.4%$1.97B$747.40M-117.95600Analyst DowngradeNBIXNeurocrine Biosciences4.7957 of 5 stars$135.99-0.6%$161.89+19.1%+24.6%$13.50B$2.51B40.261,800Analyst ForecastEXELExelixis4.8691 of 5 stars$40.94-1.0%$44.42+8.5%+52.2%$11.03B$2.17B19.691,147Positive NewsAnalyst ForecastIONSIonis Pharmaceuticals3.5439 of 5 stars$68.97+0.8%$73.88+7.1%+85.1%$10.99B$944.05M-37.461,069Trending NewsAnalyst ForecastInsider TradeGap UpEXASExact Sciences4.4236 of 5 stars$56.55+0.6%$68.52+21.2%-13.5%$10.71B$2.76B-10.417,000Analyst UpgradeBMRNBioMarin Pharmaceutical4.9484 of 5 stars$55.20-0.7%$92.60+67.8%-20.4%$10.61B$2.85B16.393,040Analyst ForecastMDGLMadrigal Pharmaceuticals4.3065 of 5 stars$451.31+0.4%$495.88+9.9%+101.6%$10.02B$180.13M-35.1390Analyst ForecastRGENRepligen4.4538 of 5 stars$149.35+2.8%$168.08+12.5%+11.7%$8.40B$673.96M-597.181,778Analyst ForecastHALOHalozyme Therapeutics4.7062 of 5 stars$68.33-4.7%$70.44+3.1%+20.5%$7.99B$1.02B15.64390Trending NewsAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies ADMA Competitors ANIP Competitors NBIX Competitors EXEL Competitors IONS Competitors EXAS Competitors BMRN Competitors MDGL Competitors RGEN Competitors HALO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LGND) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
